Physician
The Good Samaritan Hospital of Lebanon, Pennsylvania
The Good Samaritan Hospital of Lebanon, Pennsylvania was paid $18.23M by Medicaid between Feb 2018 and Dec 2024, across 303 billing codes. Its largest line is 99285, emergency room visit (most serious) — 27% of everything it billed.
33Billing provider infoTHE GOOD SAMARITAN HOSPITAL OF LEBANON, PENNSYLVANIA
LEBANON, PA 17042
LEBANON, PA 17042
33aNPI1407928500assigned 11/14/2006
33bProvider typeEmergency Medicine Physician
28Total paid$18.23M
24GClaims524,508
24DCodes billed303
24AFirst – last monthFeb 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Pennsylvania
Rank by total paid#4 of 1,211
Median peer was paid$19K
This provider vs. median935×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 157 | $10K | |
| 2019 | 2,167 | $44K | |
| 2020 | 53,343 | $1.42M | |
| 2021 | 213,114 | $6.57M | |
| 2022 | 85,912 | $3.52M | |
| 2023 | 96,633 | $3.67M | |
| 2024incomplete | 73,182 | $3.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 27% | 25,800 | 24,070 | $4.95M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 21,653 | 20,750 | $3.84M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 15,575 | 14,654 | $2.77M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.7% | 14,457 | 13,443 | $1.04M |
| G0378 | Hospital observation service, per hour | 2.2% | 482 | 448 | $394K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 2.2% | 9,764 | 4,506 | $393K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 2,038 | 1,971 | $332K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.6% | 4,807 | 4,658 | $297K |
| 80053 | Comprehensive metabolic panel | 1.1% | 32,951 | 30,752 | $206K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 4,511 | 4,180 | $189K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,056 | 1,998 | $179K |
| 81513 | <1% | 1,717 | 1,670 | $167K |
291 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,445 | $132K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,889 | $126K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,197 | $116K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,142 | $110K |
| 62323 | <1% | 163 | $109K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,298 | $108K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,209 | $108K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,009 | $104K |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,313 | $102K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,047 | $99K |
| 80050 | General health panel | <1% | 1,878 | $87K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,008 | $72K |
| 80061 | Lipid panel | <1% | 4,743 | $71K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,560 | $60K |
| 80081 | <1% | 612 | $57K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 786 | $54K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,214 | $53K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,738 | $51K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,108 | $48K |
| 84484 | <1% | 8,939 | $48K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,658 | $47K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,218 | $46K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,009 | $45K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,075 | $44K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,237 | $42K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 163 | $42K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,318 | $40K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,937 | $40K |
| 87481 | <1% | 873 | $37K | |
| 84702 | <1% | 4,533 | $35K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,452 | $33K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 171 | $31K |
| 86803 | <1% | 1,442 | $31K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 741 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 362 | $28K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,209 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 879 | $28K |
| 97161 | <1% | 478 | $27K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 595 | $27K |
| 81001 | <1% | 19,808 | $26K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 167 | $25K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,860 | $23K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 81 | $23K |
| 93971 | <1% | 454 | $23K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,750 | $22K |
| 97162 | <1% | 489 | $21K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 832 | $20K |
| 95811 | <1% | 44 | $19K | |
| 83690 | <1% | 9,031 | $18K | |
| 95800 | <1% | 193 | $18K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 756 | $18K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 685 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,107 | $17K |
| 76830 | Ultrasound, transvaginal | <1% | 610 | $17K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 941 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,001 | $17K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 141 | $16K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 82 | $16K |
| 83880 | <1% | 1,168 | $16K | |
| 93970 | <1% | 233 | $16K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 514 | $15K |
| 85027 | <1% | 2,738 | $15K | |
| 64493 | <1% | 16 | $15K | |
| 86003 | <1% | 129 | $14K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 60 | $14K |
| 76536 | <1% | 274 | $13K | |
| 76642 | <1% | 313 | $13K | |
| 71250 | <1% | 275 | $13K | |
| 83735 | <1% | 4,239 | $13K | |
| 76770 | <1% | 362 | $13K | |
| 87653 | <1% | 286 | $13K | |
| 87631 | <1% | 102 | $11K | |
| 93017 | <1% | 297 | $11K | |
| 93975 | <1% | 110 | $10K | |
| 96376 | <1% | 651 | $10K | |
| 84466 | <1% | 650 | $10K | |
| 85610 | <1% | 4,596 | $9K | |
| 82728 | <1% | 866 | $9K | |
| 86850 | <1% | 1,264 | $9K | |
| 77066 | Tomosynthesis, mammo | <1% | 94 | $9K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 326 | $9K |
| 72141 | <1% | 42 | $8K | |
| 82607 | <1% | 800 | $8K | |
| 86618 | <1% | 319 | $8K | |
| 73564 | <1% | 473 | $8K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 175 | $7K |
| 84439 | <1% | 805 | $7K | |
| 82570 | <1% | 951 | $7K | |
| 84146 | <1% | 267 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,065 | $7K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 761 | $7K |
| 87340 | <1% | 488 | $7K | |
| 87150 | <1% | 155 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 136 | $7K |
| 93976 | <1% | 125 | $7K | |
| 72110 | <1% | 308 | $7K | |
| 12001 | <1% | 72 | $7K | |
| 83605 | <1% | 2,248 | $6K | |
| 87040 | <1% | 816 | $6K | |
| 85730 | <1% | 2,272 | $6K | |
| 83013 | <1% | 86 | $6K | |
| 87077 | <1% | 1,180 | $6K | |
| 94729 | <1% | 195 | $6K | |
| 86038 | <1% | 347 | $6K | |
| 74018 | <1% | 626 | $6K | |
| 83540 | <1% | 745 | $6K | |
| 86900 | <1% | 1,636 | $5K | |
| 81025 | <1% | 4,096 | $5K | |
| 82043 | <1% | 630 | $5K | |
| 87522 | Neg quan hep c or qual rna | <1% | 121 | $5K |
| 86901 | <1% | 1,622 | $5K | |
| 94726 | <1% | 195 | $5K | |
| 87186 | <1% | 889 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 130 | $5K |
| 76801 | <1% | 245 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 186 | $5K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 234 | $5K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 42 | $5K |
| 73610 | <1% | 391 | $5K | |
| 70496 | <1% | 55 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 765 | $5K |
| 86592 | <1% | 1,027 | $4K | |
| 83655 | <1% | 358 | $4K | |
| 82784 | <1% | 183 | $4K | |
| 84153 | <1% | 195 | $4K | |
| 84481 | <1% | 146 | $4K | |
| 82950 | <1% | 529 | $4K | |
| 73030 | <1% | 399 | $4K | |
| 73630 | <1% | 489 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 101 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 44 | $3K |
| 80076 | <1% | 420 | $3K | |
| 72100 | <1% | 250 | $3K | |
| 73130 | <1% | 414 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 41 | $3K |
| 84403 | <1% | 108 | $3K | |
| 36591 | <1% | 46 | $3K | |
| 83970 | <1% | 74 | $3K | |
| 80164 | <1% | 199 | $3K | |
| 87493 | <1% | 74 | $3K | |
| 85379 | <1% | 694 | $3K | |
| 86140 | <1% | 1,426 | $3K | |
| 83516 | <1% | 164 | $3K | |
| 82105 | <1% | 136 | $3K | |
| 85652 | <1% | 1,034 | $3K | |
| 82746 | <1% | 317 | $3K | |
| 96367 | <1% | 225 | $3K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 633 | $2K |
| 82947 | <1% | 1,878 | $2K | |
| 73502 | <1% | 165 | $2K | |
| 74178 | <1% | 12 | $2K | |
| 86762 | <1% | 112 | $2K | |
| 92588 | <1% | 48 | $2K | |
| 76870 | <1% | 62 | $2K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 547 | $2K |
| 86431 | <1% | 261 | $2K | |
| 82248 | <1% | 493 | $2K | |
| 82565 | <1% | 518 | $2K | |
| 77062 | <1% | 91 | $2K | |
| 94060 | <1% | 198 | $2K | |
| 83001 | <1% | 113 | $2K | |
| 86706 | <1% | 116 | $2K | |
| 73110 | <1% | 242 | $2K | |
| 80069 | <1% | 171 | $2K | |
| 86765 | <1% | 121 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 77 | $1K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 262 | $1K |
| 84100 | <1% | 489 | $1K | |
| 82805 | <1% | 194 | $1K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 16 | $1K |
| 82550 | <1% | 344 | $1K | |
| 82378 | <1% | 86 | $1K | |
| 70498 | <1% | 27 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 42 | $1K |
| 87799 | <1% | 18 | $1K | |
| 92567 | <1% | 104 | $1K | |
| 84156 | <1% | 284 | $1K | |
| 87081 | <1% | 247 | $1K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 84 | $1K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 44 | $1K |
| 83615 | <1% | 225 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,110 | $1K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 17 | $975.02 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 24 | $940.34 |
| 72050 | <1% | 38 | $928.47 | |
| 90715 | <1% | 337 | $922.89 | |
| 80055 | <1% | 62 | $863.76 | |
| 84550 | <1% | 149 | $855.19 | |
| 87070 | <1% | 163 | $845.84 | |
| 97802 | <1% | 13 | $809.24 | |
| 83002 | <1% | 50 | $794.40 | |
| 84520 | <1% | 352 | $783.57 | |
| 95886 | <1% | 14 | $780.52 | |
| 86376 | <1% | 87 | $773.97 | |
| 87512 | <1% | 29 | $707.05 | |
| 81003 | <1% | 218 | $705.72 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 59 | $660.83 |
| 73590 | <1% | 77 | $652.20 | |
| 72072 | <1% | 38 | $639.46 | |
| A9270 | Non-covered item or service | <1% | 271 | $639.40 |
| 83525 | <1% | 50 | $625.93 | |
| 87427 | <1% | 58 | $615.27 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,107 | $609.40 |
| 87205 | <1% | 203 | $559.42 | |
| 87209 | <1% | 26 | $555.95 | |
| 86787 | <1% | 26 | $509.16 | |
| 80051 | <1% | 197 | $507.33 | |
| 86704 | <1% | 29 | $504.80 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,595 | $478.02 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,191 | $426.60 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,193 | $424.41 |
| 82951 | <1% | 29 | $419.05 | |
| 87147 | <1% | 158 | $412.59 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 99 | $412.50 |
| 86200 | <1% | 29 | $403.43 | |
| 86235 | <1% | 14 | $397.32 | |
| 83020 | <1% | 28 | $383.95 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,275 | $374.69 |
| 85018 | <1% | 115 | $356.35 | |
| 87045 | <1% | 58 | $348.61 | |
| 84402 | <1% | 12 | $346.32 | |
| 83721 | <1% | 45 | $335.89 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $331.50 |
| 86255 | <1% | 14 | $301.04 | |
| 92557 | <1% | 13 | $288.56 | |
| 83921 | <1% | 13 | $252.48 | |
| C1769 | Guide wire | <1% | 53 | $251.25 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,473 | $250.15 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 595 | $240.66 |
| S9470 | Nutritional counseling, dietitian visit | <1% | 15 | $238.56 |
| 88304 | <1% | 111 | $232.79 | |
| 86708 | <1% | 13 | $232.50 | |
| 74022 | <1% | 14 | $223.40 | |
| 76882 | <1% | 28 | $223.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,348 | $209.16 |
| 85014 | <1% | 70 | $207.86 | |
| 87177 | <1% | 26 | $207.64 | |
| 84145 | <1% | 47 | $206.65 | |
| 82010 | <1% | 163 | $193.68 | |
| 29125 | <1% | 13 | $191.79 | |
| 87046 | <1% | 58 | $188.50 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 542 | $177.18 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 886 | $167.62 |
| 85046 | <1% | 32 | $164.84 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 927 | $158.60 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 793 | $155.59 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,719 | $146.50 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,744 | $143.45 |
| 71101 | <1% | 13 | $139.25 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,717 | $137.42 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 896 | $130.81 |
| 12011 | <1% | 13 | $119.99 | |
| 82310 | <1% | 15 | $103.66 | |
| 82952 | <1% | 28 | $101.04 | |
| 51701 | <1% | 14 | $99.34 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 756 | $94.03 |
| 84425 | <1% | 12 | $87.50 | |
| J1815 | Injection, insulin, per 5 units | <1% | 869 | $81.92 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 38 | $77.80 |
| 36600 | <1% | 24 | $63.64 | |
| 99152 | <1% | 15 | $61.90 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,632 | $61.80 |
| 82150 | <1% | 14 | $58.75 | |
| 73140 | <1% | 12 | $53.55 | |
| 82270 | <1% | 40 | $48.60 | |
| 73090 | <1% | 13 | $44.98 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 311 | $44.02 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 131 | $43.20 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 650 | $33.64 |
| 84155 | <1% | 14 | $29.55 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,671 | $24.36 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 552 | $13.12 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 149 | $5.68 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 306 | $1.91 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 12 | $1.23 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 311 | $0.01 |
| J3490 | Unclassified drugs | 0% | 844 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 335 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 97 | $0.00 |
| 64494 | 0% | 24 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 39 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 18 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 21 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 235 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 97 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 200 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 87 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 557 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 103 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 76 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCITRO, TINA (VP & PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| The Good Samaritan Hospital of Lebanon, Pennsylvania | Lebanon, PA | $3.48M |
| The Good Samaritan Hospital of Lebanon, Pennsylvania | Lebanon, PA | $53K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.